Rising Lifetime Risk of Atrial Fibrillation and Its Complications

Study reveals increasing lifetime risk of atrial fibrillation, emphasizing urgent need for preventive strategies against stroke and heart failure in affected individuals.

A recent study from Denmark published in The BMJ reveals that the lifetime risk of atrial fibrillation (AF), a heart condition characterized by irregular and rapid heartbeats, has risen from 1 in 4 to 1 in 3 over the last two decades ().

The study also shows that among individuals diagnosed with AF, 2 out of 5 are likely to develop heart failure during their remaining lifespan, and 1 out of 5 will experience a stroke. Unfortunately, there has been minimal improvement in these risks over the 20-year study period.

Atrial Fibrillation - Causes, Symptoms, Diagnosis, Treatment, Complication, Risks
Atrial fibrillation may not be life-threatening in itself but it is important to understand the causes, symptoms and treatments because of the risk of life-threatening complications.

‘Atrial fibrillation patients face a 41% lifetime risk of heart failure, twice that of stroke. #hearthealth #strokeprevention #medindia’

Therefore, the researchers emphasize the urgent need for effective strategies to prevent strokes and heart failure in people with atrial fibrillation.

Implications of Rising Atrial Fibrillation Lifetime Risk

Atrial fibrillation is estimated to affect 18 million people in Europe by 2060 and 16 million people in the US by 2050. In the English NHS alone, more new cases of atrial fibrillation are diagnosed each year than the four most common causes of cancer combined, and direct expenditure on atrial fibrillation has reached £2.5 billion.

Once atrial fibrillation develops, patient care has primarily focused on the risk of stroke, but other complications such as heart failure and heart attack have yet to be fully explored.

Vitamin C may Help Lower the Risk of Post-Operative Atrial Fibrillation
Heart patients are likely to suffer from atrial fibrillation or irregular heart beat. Administration of vitamin C can decrease the risk of atrial fibrillation.

To address this knowledge gap, researchers analysed national data for 3.5 million Danish adults with no history of atrial fibrillation at age 45 or older to see whether they developed atrial fibrillation over a 23 year period (2000-22).

All 362,721 individuals with a new diagnosis of atrial fibrillation during this time (46% women and 54% men) but with no complications, were subsequently followed until a diagnosis of heart failure, stroke or heart attack.

Blood Thinner for Atrial Fibrillation Tied With High Bleeding Risk
The blood thinner drug Rivaroxaban has a higher bleeding risk compared to warfarin and apixaban, the common blood thinners used for atrial fibrillation.

Potentially influential factors such as history of high blood pressure, diabetes, high cholesterol, heart failure, chronic lung and kidney disease, family income and educational attainment, were also taken into account.

The results show that the lifetime risk of atrial fibrillation increased from 24% in 2000-10 to 31% in 2011-22. The increase was larger among men and individuals with a history of heart failure, heart attack, stroke, diabetes, and chronic kidney disease.

Dark Chocolate can Lower the Risk of Atrial Fibrillation
Regular consumption of chocolate, particularly dark chocolate can lower the risk of atrial fibrillation in women by 21 percent and in men by 23 percent.

Among those with atrial fibrillation, the most common complication was heart failure (lifetime risk 41%). This was twice as large as the lifetime risk of any stroke (21%) and four times greater than the lifetime risk of heart attack (12%).

Long-Term Consequences of Atrial Fibrillation Complications

Men showed a higher lifetime risk of complications after atrial fibrillation compared with women for heart failure (44% vs 33%) and heart attack (12% vs 10%), while the lifetime risk of stroke after atrial fibrillation was slightly lower in men than women (21% vs 23%).

Over the 23-year study period, there was virtually no improvement in the lifetime risk of heart failure after atrial fibrillation (43% in 2000-10 vs 42% in 2011-22) and only slight (4-5%) decreases in the lifetime risks of any stroke, ischemic stroke, and heart attack after atrial fibrillation, which were similar among men and women.

This is an observational study, so no firm conclusions can be drawn about cause and effect, and the authors acknowledge that they may have missed patients with undiagnosed atrial fibrillation. Nor did they have information on ethnicity or lifestyle factors, and say results may not apply to other countries or settings.

But despite these caveats, they conclude: “Our novel quantification of the long term downstream consequences of atrial fibrillation highlights the critical need for treatments to further decrease stroke risk as well as for heart failure prevention strategies among patients with atrial fibrillation.”

Interventions to prevent stroke have dominated atrial fibrillation research and guidelines during this study period, but no evidence suggests that these interventions can prevent incident heart failure, say UK researchers in a linked editorial.

They call for alignment of both randomised clinical trials and guidelines “to better reflect the needs of the real-world population with atrial fibrillation” and say this robust observational research “provides novel information that challenges research priorities and guideline design, and raises critical questions for the research and clinical communities about how the growing burden of atrial fibrillation can be stopped.”

Reference:

Temporal trends in lifetime risks of atrial fibrillation and its complications between 2000 and 2022: Danish, nationwide, population based cohort study - (https://www.bmj.com/content/385/bmj-2023-077209)

Source-Medindia